Abstract:Some small molecules, often hits from screening, form aggregates in solution that inhibit many enzymes. In contrast, drugs are thought to act specifically. To investigate this assumption, 50 unrelated drugs were tested for promiscuous inhibition via aggregation. Each drug was tested against three unrelated model enzymes: beta-lactamase, chymotrypsin, and malate dehydrogenase, none of which are considered targets of these drugs. To be judged promiscuous, the drugs had to inhibit all three enzymes, do so in a time-dependent manner, be sensitive to detergent and to enzyme concentration, and form particles detectable by light scattering. Of the 50 drugs tested, 43 were nonpromiscuous by these criteria. Surprisingly, four of the drugs showed promiscuous, aggregation-based inhibition at concentrations below 100 microM: clotrimazole, benzyl benzoate, nicardipine, and delavirdine. Three other drugs also behaved as aggregation-based inhibitors, but only at high concentrations (about 400 microM). To investigate possible structure-activity relationships among promiscuous drugs, five analogues of the antifungal clotrimazole were studied. Three of these, miconazole, econazole, and sulconazole, were promiscuous but the other two, fluconazole and ketoconazole, were not. Using recursive partitioning, these experimental results were used to develop a model for predicting aggregate-based promiscuity. This model correctly classified 94% of 111 compounds-47 aggregators and 64 nonaggregators-that have been studied for this effect. To evaluate the model, it was used to predict the behavior of 75 drugs not previously investigated for aggregation. Several preliminary points emerge. Most drugs are not promiscuous, even at high concentrations. Nevertheless, at high enough concentrations (20-400 microM), some drugs can aggregate and act promiscuously, suggesting that aggregation may be common among small molecules at micromolar concentrations, at least in biochemical buffers.

Identification of Small Molecule Aggregators from Large Compound Libraries by Support Vector Machines

Structural Analysis and Identification of Colloidal Aggregators in Drug Discovery.

Combating small molecule aggregation with machine learning

Virtual Screening of Abl Inhibitors from Large Compound Libraries by Support Vector Machines.

Development and Experimental Test of Support Vector Machines Virtual Screening Method for Searching Src Inhibitors from Large Compound Libraries.

Mitigating Molecular Aggregation in Drug Discovery with Predictive Insights from Explainable AI

Combinatorial Support Vector Machines Approach for Virtual Screening of Selective Multi-Target Serotonin Reuptake Inhibitors from Large Compound Libraries

Effect of training data size and noise level on support vector machines virtual screening of genotoxic compounds from large compound libraries

Predicted Model of Aggregation of Molecules in Chinese Herbal Drugs by Support Vector Machines

Classification of 5-HT(1A) Receptor Agonists and Antagonists Using GA-SVM Method.

Evaluation of Virtual Screening Performance of Support Vector Machines Trained by Sparsely Distributed Active Compounds

A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor

Virtual Screening of Selective Multitarget Kinase Inhibitors by Combinatorial Support Vector Machines

Prediction of P-Glycoprotein Substrates by a Support Vector Machine Approach

Classification of Src Kinase Inhibitors Based on Support Vector Machine

Identifying P-Glycoprotein Substrates Using a Support Vector Machine Optimized by a Particle Swarm.

Identification and prediction of promiscuous aggregating inhibitors among known drugs

Molecular dynamics simulations as a guide for modulating small molecule aggregation

Identifying Novel Type Zbgs and Nonhydroxamate Hdac Inhibitors Through A Svm Based Virtual Screening Approach

Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation

Support Vector Machine (SVM) Models for Predicting Inhibitors of the 3' Processing Step of HIV-1 Integrase